Kheiron develops Mia™, software designed to analyse standard Full Field Digital mammography (FFDM) images in a breast cancer screening setting and assist radiologists in recall decisions. Mia™ has demonstrated performance in a multi-centre clinical study. The product was developed by a team of machine learning specialists, radiologists and imaging industry experts with backgrounds at Imperial College, The Royal Marsden, University College London, Edinburgh, Oxford, GE and Philips. Kheiron intends to use new funding to further scale the clinical validation of Mia™, including conducting large-scale clinical trials and roll-outs in Europe, the United States and Asia to assess and demonstrate clinical effectiveness and safety. First deployments for live testing and further trials are affiliated with the UK’s National Health Service (NHS) and academic medical centers in the US. The company is led by CEO Dr. Peter Kecskemethy.

Total raised

$22M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2019